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Dementia has been declared a Global Challenge [1]. However, strategies to tackle it are far 
from global. Epidemiological forecasts are more alarming for low and middle-income 
countries (LMIC) than for high-income countries (HIC), and yet provisions to support the 
former are scarce and, in some cases, as we discuss below, impractical. New initiatives are 
emerging to close these gaps. The Latin America and Caribbean Consortium on Dementia 
(LAC-CD) [2] and the Global Dementia Prevention Program (GloDePP Consortium; Wang, H. 
from Peking University and Chan, K.Y. from University of Edinburgh. Preventing dementia and 
improving dementia care: setting and addressing research priorities in China. Supported by 
Global Challenges Research Fund Networking Grants). They are seeking strategies to meet 
and map local and global challenges. Both consortia agree that actions to improve diagnosis 
and post-diagnostic support are of utmost priority. Here we discuss theory-driven, culturally 
valid, and interdisciplinary approaches that can yield affordable, reliable, and practical 
solutions to meet these outstanding needs.  
 
Cognitive ageing in LMIC 
How to manage and treat our ageing population is of critical concern to governments and 
healthcare providers across the world. Globally, due to declining fertility rates and increasing 
life expectancies, we are experiencing rapid population ageing. Within developing countries, 
age-related mortality is often viewed within the context of poverty, disease, and conflict, with 
little focus on the growing rates of dementia that rise in line with a growing population of 
older adults [3]. In 2015, Alzheimer’s Disease International (ADI) reported that there are over 
9.9 million new cases of dementia each year worldwide, implying one new case every 3.2 
seconds [4]. Investigations of the incidence rates in HIC have yielded a number of encouraging 
results. For example, in the UK, the Medical Research Council Cognitive Function and Ageing 
Studies I and II suggest the incidence rate for dementia has fallen by 20% over 20 years (with 
this mostly occurring in men) [5].  Likewise, in the USA - Framingham Heart study – incidence 
rates are reported to have dropped by a rate of approximately 20% per decade [6]. These 
decreases may be linked to factors such as those associated with reduced vascular risk [7]. In 
LMIC, despite reports that the incidence rate is 10% lower than in HICs, the risk profile is 
shifting in the opposite direction, with LMIC tending to exhibit increasing cardiovascular risk, 
suggesting that incidence rates might increase in these countries [4]. As the incidence and 
average duration of a disease determine its prevalence, globally the number of people living 
with dementia is increasing. ADI reported [8] that 46.8 million people worldwide live with 
dementia, and that this number will almost double every 20 years, to 74.7 million in 2030 and 
131.5 million in 2050. They suggested that such an increase in prevalence would be 
attributable to increases in the numbers of people with dementia in LMIC. In 2015, 58% of all 
people with dementia lived in LMIC, and this is expected to rise to 63% in 2030 and 68% in 
2050. Parra et al. [2] have recently identified factors linked to such an increase, among which, 
age, education, and changes in health care infrastructure were highlighted. However, more 
and better designed epidemiological studies are needed to identify the sources of such 
increases which, at present and for many countries, are still estimates from prediction models 
supported by the limited data available [2,4]. These countries must now adapt to ageing 
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populations more quickly, and with comparatively fewer resources, than countries whose 
demographic ageing began much earlier. 
Cognitive impairment is among the most feared aspects of ageing, and is a legitimate age-
related health concern, potentially affecting wellbeing and independence. Crucially, 
individual differences play a role, and high cognitive ‘reserve’ is associated with greater 
resilience to the symptomology associated with Alzheimer’s disease (AD) [9]. Factors such as 
educational and occupational attainment are related to enhanced reserve, in terms of brain 
and cognitive functional capacity. Hypothetically, those with high reserve will tolerate 
pathology for longer, before reaching clinical levels of functioning. They would also exhibit 
reduced clinical severity, especially at the mild pathology stage, at which they may appear 
clinically normal. It has been recently reported that the education-dementia link in LMIC such 
as Latin American Countries is strong [10] and that although the mechanisms underpinning 
such a link are unclear, the concept of cerebral and cognitive reserve [9] offers a plausible 
explanation. Later in this opinion piece we shall address how such factors underpin various 
challenges faced by LMIC. For instance, mediators of cognitive reserve such as intellectual and 
lifestyle factors, can modify the course of ageing and render the task of separating normal 
and abnormal ageing trajectories an arduous one. We next discuss how interactions among 
such factors affect assessment of cognition late in life. 
 
Culturally valid assessments 
Despite the gradual shift towards biologically oriented approaches to document the presence 
of AD [11], diagnostic criteria for dementia require evidence of cognitive decline which can 
be provided only via formal psychometric testing. Developing reliable neuropsychological 
tests to aid the diagnosis of dementia has proved a difficult task. From independent meetings 
recently held by LAC-CD and GloDePP, it has been acknowledged that the challenges 
experienced by countries across the globe are very similar (see Box 1). Heterogeneity of 
assessment procedures (i.e., clinical, neuropsychological, functional scales), lack of 
standardization, and sensitivity to demographic factors (i.e., education, literacy, cultural 
idiosyncrasies, and environment) are shared barriers which need urgent action.  For effective 
utilisation globally, optimal cognitive markers of AD should be highly sensitive and specific to 
its pathology, whereas they should be unaffected by healthy ageing, other types of dementia 
pathology, and the cultural background and literacy levels of those assessed. A new test, 
namely the Short-Term Memory Binding Test (STMBT; [12]), has been recently recommended 
by international consensus as it meets these criteria [13]. What features grant the STMBT 
such psychometric properties? The STMBT is a change detection task that presents stimuli 
that hold neither verbal properties nor long-term memory representations. The test taxes low 
level visual functions which draw little support from literacy or education. The test relies on 
a simple set of instructions (i.e., detect differences across two consecutive visual arrays), 
thereby limiting any challenge for people with little formal education. The STMBT is not 
affected by prior knowledge, experience, or practice effects. These properties may hold the 
key to addressing long-standing limitations of neuropsychological tests. 
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Informant-based interviews (e.g., AD8; [14]) are proving useful screening tools and are being 
validated in LMIC. However, awareness and stigma are barriers that may undermine their 
usefulness in such countries. There is consensus that proxy measurements should be 
complementary to the direct assessment of patients. This is even more relevant if we consider 
that informant-based interviews discriminate between nondemented individuals and those 
with cognitive impairment regardless of the aetiology. There is a need for assessment tools 
that are both sensitive and specific. For example, the STMBT suggested above holds both high 
sensitivity and specificity for AD [12, 15,16]. Therefore, brief informant-based interviews and 
objective assessment such as the STMBT can be combined in LMIC settings to investigate their 
complementary value. 
Why are cultural factors so relevant? A neuropsychological assessment for clinical purposes 
may be considered to have cross-cultural bias if there are significant cultural or language 
differences between the examiner, examinee, informants, tests, and/or social contexts. Most 
of the neuropsychological tests available in LMIC meet several of these criteria (see [2]). 
Assessment tools available to LMIC have been adapted from developed countries, and 
although properly translated, they do not account for cultural variation. Similar cognitive 
constructs may show different sensitivity to sociodemographic factors. For example, the 
STMBT and the Memory Binding Test (MBT) (see [13]) assess binding functions seemingly 
affected in the preclinical stages of dementia. Contrary to the STMBT, the MBT relies on free 
and cued selective reminding procedures, presents verbal materials which hold long-term 
memory representations, taxes associative memory functions which heavily rely on literacy 
and education, and is affected by prior knowledge and repetition effects. The former but not 
the latter test has proved insensitive to the level of education of the assessed individual. LMIC 
will need tests that circumvent the effects of such sociodemographic factors. 
 
Providing evidence of brain pathology 
The new lexicon to define AD entails not only the documentation of cognitive impairment but 
of neuropathology. Within this new context, preclinical detection would require biomarker-
based decisions and biomarker-focused computer-based algorithms for phenotyping and 
building risk profiles.  
Biomarkers may be used to increase the certainty of diagnosis of AD.  The recent A-T-N 
framework [11] emphasizes the hallmark features of AD, such as deposition of amyloid-beta 
(A) and changes in tau (T), and their identification with positron emission tomography or 
lumbar puncture. Accumulation of these abnormal proteins are associated with 
neurodegeneration (N) which normally triggers the clinical phase of the disease. These 
biomarkers are not frequently used in clinical practice, and given the cost, specialized 
equipment, invasiveness, and required clinical expertise (for data collection and analysis), 
they are unlikely to be widely available any time soon [8]. Complying with this emerging 
framework and attempting to adopt these biomarker methodologies presents LMIC with a 
set of important challenges. To overcome these, LMIC may instead turn towards novel proxy-
biomarkers to improve confidence in diagnosis. It may be possible to develop high accuracy 
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blood-based biomarkers for the detection of AD (that are minimally invasive and low-cost). In 
addition to targeted proteomics and metabolomics, data-driven methods may provide novel 
biomarkers which can rely on machine learning classifiers. For example, spectroscopic 
methods that provide biochemical profiles of blood serum/plasma, with subsequent 
classification using techniques such as artificial neural networks, have provided encouraging 
preliminary results for both sensitivity and specificity, albeit with small sample sizes (e.g., 
[17]). 
Electroencephalography (EEG) systems may also be used to enhance certainty of diagnosis.  
EEG is non-invasive, non-costly, widely available, and requires minimal clinical training. It 
offers an alternative biomarker, one that provides key information on the integrity of synaptic 
functioning, the disruption of which has also been detected very early in the disease course 
[18]. EEG biomarkers may focus on event-related potentials or resting state recordings, and 
on measures such as amplitude, coherence, synchronization likelihood, entropy, graph 
theory, phase-lag index, and Lempel-Ziv complexity (see [19] for a review).  Progress is also 
being made in validating EEG biomarkers against other more standard markers of disease 
(e.g., [20]). Standard EEG systems may already be available in hospitals/clinics in LMICs or, 
failing that, mobile EEG systems may be purchased at low cost. Mobile EEG may provide a 
promising avenue for assessment as the equipment is cheap to run, fast to set-up, can be 
transferred easily amongst settings, and can be applied with minimal training for the operator 
[21]. 
Recent evidence suggests that oculomotor behaviours linked to cognitive performance can 
yield additional biomarkers of AD (See Box 1). Several potential oculomotor biomarkers of the 
disease have been identified in recent decades. Established deficits have been seen in higher 
level cognitive activities such as our ability to smoothly pursue a visual target, or our ability 
to inhibit a saccade and volitionally generate an antisaccade, in the oculomotor behaviour of 
reading and in low level physiological characteristics including pupil diameter, blink rate, and 
the speed of reflexive saccades [22]. The analysis of gazing and pupil responses during STMB 
performance significantly predicts the presence of AD pathology [23]. Gazing and pupil 
behaviours rest on a network that involves cortical and subcortical structures starting from 
the brainstem. It has been suggested that synaptic and circuit-level disruptions of subcortical 
systems controlling oculomotor responses are an early feature of AD which can potentially 
lead to amyloid accumulation and to the progression of neurodegeneration. Hence, the 
information drawn from eye movement behaviours linked to cognitive markers holds value 
as a potential biomarker for the disease. 
As disease-modifying pharmacological treatments are not yet available, there is growing 
concern as to whether and how biomarker evidence would guide strategies to tackle this 
common disorder. We next address issues related to promising non-pharmacological 
interventions. 
 
Affordable interventions for dementia 
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As both genetic and lifestyle factors can account for variation in age-related cognitive change, 
there is clear opportunity to develop lifestyle interventions that could help increase ‘healthy 
life expectancy’ across the globe. For example, cognitive and physical activity levels as well as 
healthy diets, throughout the lifespan, are believed to help compensate for declines in 
cognitive and brain functioning (‘plasticity’). Indeed, observational studies have highlighted 
positive relationships between cognitive stimulation and cognitive outcomes. Additionally, 
‘real-world’ research is vitally important, both for informing future policy and practice, and 
for developing accessible, attractive intervention programmes that are feasible to implement 
on a large scale. It is also possible for community-based interventions, such as 
intergenerational engagement programmes, to bring wider societal benefits. In the area of 
lifestyle interventions, the use of technological developments is also opening new windows 
of opportunity (see Box 1). 
Prince et al. [24] looked at packages of care for dementia in LMIC. The review of the status 
quo of non-pharmacological approaches in HIC and LMIC confirms the need of more studies 
across such countries. The LAC-CD is currently drafting a knowledge-to-action framework 
which incorporates a Non-Pharmacological Intervention programme. This programme aims 
to introduce approaches which might prove feasible in the region due to social, cultural, 
idiosyncratic, and environmental factors. Examples are cognitive therapy, art therapy, 
musicotherapy, touch, animal assisted therapy, exercise, horticultural therapy, information 
and communication technologies interventions (computerized training, virtual reality and 
robotics), cognitive tele-rehabilitation, emotional intervention, and sensory stimulation. 
Experts from the region agreed that access to internet and ICT is rapidly growing in LAC. 
Hence, this would create opportunities to capitalise on emerging technologies to introduce 
these forms of intervention and validate them. 
Dementia is particularly damaging to an individual’s independence and overall quality of life 
(e.g., as a result of loss of memory and optimal judgement). However, it also affects those 
around the patient, who must take on the role of care giver, as patients’ personalities are 
slowly eroded, and whose mood and behaviour can become erratic. In light of this, a greater 
focus and more targeted interventions are required to ensure that those who develop 
dementia, and their caregivers, are provided with modern and cost-effective tools to manage 
this disease. In developed nations, the advent of virtual/augmented reality (VR/AR) 
technology is receiving greater attention, as a means of treating and managing a range of 
psychological/psychobiological disorders. In the case of dementia, the use of VR/AR is in its 
infancy (see [25]). However, there seems to be consensus that such technologies can help 
mitigate behavioural and psychological symptoms of patients having MCI and early-stage AD, 
better addressing their specific rehabilitation needs, as well as their caregivers’ intervention 
requirements [26,27]. This is particularly the case as the sophistication of the equipment 
increases along with a year-on-year reduction in cost (i.e., related technology is now available 
via smart phones). In light of these advances in, and application of, VR/AR technologies, 
governments and healthcare providers should now look at the benefits that such an approach 
could bring to the management and treatment of dementia in LMIC.  
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In Box 1.B we have presented a list of solutions which can pave the way towards global 
strategies to tackle the dementia challenge. However, there still remain significant barriers to 
the implementation of such strategies. Among these, stigma and socio-cultural factors in LMIC 
are worth highlighting. The ADI’s 2012 report [28] reveals that stigma and social exclusion are 
major barriers for people with dementia and their caregivers. ADI reported that 24% of people 
with dementia and more than one in ten carers (11%) hide or conceal the diagnosis. Patients 
under the age of 65 fear facing issues in their workplace or children’s school. Social exclusion 
was identified in 40% of people with dementia with nearly 60% reporting that friends are the 
most likely people to avoid them followed by family members. To overcome such barriers, a 
significant amount of work with relevant stakeholders is needed. An emerging approach that 
could help bridge these gaps is Implementation Science [29]. The strategies here proposed 
are well aligned with factors that determine the implementation success. The solutions 
proposed in Box 1.B are cost-effective, relatively easy to implement, and can be flexibly 
adapted to the heterogenous socio-cultural contexts found in LMIC. More awareness is 
needed among relevant stakeholders and the general public [28]. Governments need to 
support the development of national dementia plans which health care workers, 
policymakers, and patients could adopt, carry out, and benefit from. Researchers from LMIC 
need to interact with such stakeholders to better understand the knowledge gaps and find 
answers to the challenges facing these groups. As Prince et al. [24] pointed out, more work is 
needed to assess whether packages of care for dementia developed in HIC can be 
implemented in LMIC. The strategies here proposed provide cues towards implementation 
actions. They are aimed at fostering collaborations between HIC and LMIC and it will be 
through such collaborations that these outstanding needs will be more rapidly addressed. We 
have seen progress over the last decade. Culture-free assessment methods developed in HIC 
[12] are now widely used in LMIC (e.g., South America, [30]). A shared understanding of 
regional barriers that prompt urgent action is being fomented among relevant stakeholders 
of LAC-CD (see [2]). The model developed by this consortium could be generalised, and 
Implementation Science can provide the framework to help build such bridges. 
 
Conclusion 
 
This opinion piece has highlighted strategies that can bridge gaps in LMIC. More work is 
needed to incorporate promising cognitive constructs (e.g., memory binding) into culturally 
valid tests that can help separate normal from abnormal ageing trajectories. Such novel forms 
of cognitive assessment can be combined with affordable technologies to provide biomarker 
evidence of brain pathology which may further increase sensitivity and specificity. Cognitive 
biomarkers relying on these methodologies can be made available across health care levels, 
particularly in primary care for use in the community. By combining interventions that 
promote healthy lifestyles and novel technologies that empower patients and caregivers, it 
will be possible to foster cognitive reserves, slow cognitive decline, and prolong independent 
living. Collaborations that integrate international and interdisciplinary efforts will accelerate 
the delivery of more global solutions for tackling the dementia challenge. 
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Box 1. (A) The Latin America and Caribbean Consortium on Dementia (LAC-CD) and the Global 
Dementia Prevention Program (GloDePP Consortium) are two emerging initiatives which hold 
potential to bridge LMIC and HIC across the globe, to globalise dementia strategies. (B) 
Mapping challenges to solutions, barriers and strategies to bridge local to global actions to 
empower LMIC in the fight against dementia. 
 
 
 
Challenges 
 
 
Solutions 
 
 
Barriers 
 
 
Strategies 
Culturally valid 
assessments  
1. To develop 
theory-driven 
cognitive tests to 
discriminate 
between normal 
ageing, non-
progressive 
cognitive 
impairment, other 
types of dementia, 
or depression. (a) 
2. To rely on 
bespoke rather 
than off-the-shelf 
assessments.  
1. Shared 
understanding of 
theory-driven 
assessments (i.e., 
cognitive constructs 
underpinning these 
assessments). 
2. Interactions 
between ageing, 
culture, and 
environment (e.g., 
ethnographic 
factors 
underpinning 
stigma and social 
barriers). 
1. To set up 
worldwide 
initiatives to raise 
awareness of 
challenges shared 
across LMIC (e.g., 
linking LAC-CD & 
GloDePP). 
2. To work with 
Diversity and 
Disparity 
Initiatives to 
explore and 
promote 
strategies that 
capture the 
(A) 
(B) 
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3. To avoid verbal 
tests which rely on 
literacy. 
4. To tax low level 
functions (process 
pure) rather than 
complex 
multidimensional 
abilities. 
5. To consider 
relevant cognitive 
constructs within 
cultural and 
behavioural 
contexts (b). 
6. To validate 
culturally 
unbiased tests 
across a range of 
equivalent tests 
currently 
available. 
3. Training of 
healthcare 
providers. 
4. Cultural 
heterogeneity 
between and within 
countries (i.e., 
ethnic minorities, 
stigma). 
5. Lack of shared 
platforms for data 
collection, sharing, 
and big data 
analysis. 
 
heterogenous 
features that 
preclude 
standardization 
of assessments (c). 
3. To set up 
communication 
forums (e.g., 
websites, 
workshops) to 
enable 
interactions, 
share practices, 
and encourage 
collaboration. 
4. To develop 
integrated data 
collection, 
analysis, and 
sharing 
platforms. 
Providing 
evidence of brain 
pathology 
1. To combine 
cognitive markers 
and low-cost 
technologies that 
can collect 
biological data 
(e.g., eye-
tracking). (d) 
2. The STMBT 
appears 
promising, and 
when combined 
with EEG, 
accuracy of 
discrimination 
should further 
increase (e). 
3. Data upload by 
LMIC clinics for 
cloud-based 
automated 
analysis and 
production of 
feedback reports. 
1. Training of health 
care providers and 
community workers 
to use novel 
technologies for 
dementia.  
2. Identification of 
optimal set ups for 
portable 
assessments (e.g., 
EEG, eye-tracking).  
3. Determining how 
paradigm delivery 
could be 
uniform/controlled 
across assessment 
sites. 
4. Large sample sizes 
are required for the 
data-driven 
development of 
blood-based 
biomarkers. 
5. Blood-based 
biomarkers should 
1. Interdisciplinary 
efforts from 
computer 
sciences and 
biomedical 
engineering is 
opening new 
opportunities to 
implement 
robust methods 
such as machine 
learning 
algorithms 
towards data 
reduction, 
enhanced 
classification and 
diagnosis, and 
effective analytic 
pipelines for EEG 
data. (f) 
2. Behavioural 
analytics will 
support the 
development of 
10 
 
4. Data-driven 
analyses have the 
potential to yield 
novel blood-based 
biomarkers. 
 
be developed by 
training, testing and 
validating classifier 
models on diverse 
populations. 
 
potential 
oculomotor 
biomarkers for 
dementia. 
3. Large scale 
longitudinal 
research, 
acquiring a range 
of oculomotor 
metrics through 
tablets and 
phones, and 
alongside more 
established 
testing regimes, 
has the potential 
through machine 
learning to 
revolutionise 
both the 
diagnosis and the 
management of 
dementia. 
4. Exploit data-
sharing initiatives 
and 
biorepositories 
to acquire 
sufficient data 
for classifier 
development. 
5. Develop low-cost 
technologies for 
point-of-care 
blood sampling 
and analytics. 
6. Explore routes 
for scalable 
delivery of low-
cost peripheral 
biomarkers for 
dementia. 
7. Capitalise on 
emerging 
initiatives aimed 
at supporting the 
development of 
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peripheral 
biomarkers for 
dementia. (g,h) 
Affordable 
interventions for 
dementia 
1.Lifestyle 
interventions that 
could help increase 
‘healthy life 
expectancy’ across 
the globe. (i) 
2.Use of technology 
(e.g., VR/AR) to 
slow decline, 
restore functions, 
and prolong 
independent living. 
(j) 
1. Limited awareness 
about the benefits 
of non-
pharmacological 
interventions and 
healthy lifestyles.  
2. Cultural, socio-
economic, and 
ethical barriers 
which may deter 
patients and family 
members from 
using technology 
for intervention 
purposes. (j) 
1. Use of 
information 
technologies to 
foster a cultural 
move towards 
healthier 
lifestyles. (k) 
2. Interventions for 
dementia relying 
on VR/AR 
platforms should: 
i) be available for 
home use, 
reducing the 
financial/time 
pressure on users 
and local 
healthcare 
providers. ii) 
Ensure that cloud-
based tutorials are 
developed to 
enable care-giver 
training and safe 
use of technology 
remotely.   
3. Ethnographic 
studies to unveil 
barriers to 
implement 
technological 
development in 
LMIC. 
Sources: 
 
(a) Logie, R.H., et al. Policy Insights from the Behavioral and Brain Sciences 2015; 2: 81-91.  
(b) Parra, M.A. Dementia & Neuropsychologia 2014; 8: 95-98. 
(c) Babulal, G., et al. Alzheimer’s & Dementia 2018; in press. 
(d) Fernandez, G., et al. Alzheimer's & Dementia 2018; 14:P399-P400. 
(e) Pietto, M., et al. Journal of Alzheimer’s Disease 2016; 53: 1325-40. 
(f) Richiardi J., et al. IEEE Signal Processing Magazine 2013; ,30: 58 – 70. 
(g) Khan T.K. & Alkon, D.L. Journal of Alzheimer’s Disease 2015; 44: 729-744. 
(h) https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-
accelerator  
(i) Kivipelto, M., et al. Nature Review Neurology 2018; 14: 653-666.  
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(j) Marasinghe, K.M., et al. BMJ Innovations 2015; 1: 182-195.  
(k) Vaportzis, E., et al. American Journal of Geriatric Psychiatry 2017; 25: 841-851.  
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